Regulatory Exclusivity Expiring in 2029
Drugs with Regulatory Exclusivity Expiring in 2029
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Exclusivity Expiration | Patented / Exclusive Use |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Vertex Pharms Inc | ALYFTREK | deutivacaftor; tezacaftor; vanzacaftor calcium | TABLET;ORAL | 218730-001 | Dec 20, 2024 | RX | Yes | No | ⤷ Start Trial | NEW CHEMICAL ENTITY | |
| Vertex Pharms Inc | ALYFTREK | deutivacaftor; tezacaftor; vanzacaftor calcium | TABLET;ORAL | 218730-002 | Dec 20, 2024 | RX | Yes | Yes | ⤷ Start Trial | NEW CHEMICAL ENTITY | |
| Xcovery | ENSACOVE | ensartinib hydrochloride | CAPSULE;ORAL | 218171-001 | Dec 18, 2024 | RX | Yes | No | ⤷ Start Trial | NEW CHEMICAL ENTITY | |
| Xcovery | ENSACOVE | ensartinib hydrochloride | CAPSULE;ORAL | 218171-002 | Dec 18, 2024 | RX | Yes | Yes | ⤷ Start Trial | NEW CHEMICAL ENTITY | |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Exclusivity Expiration | >Patented / Exclusive Use |
